Salute e Benessere
Residual DNA Testing to Hit $370M by 2030 -- The Silent Guardian of Biologics Safety | MarketsandMarkets™
The global , valued at US$0.27 billion in 2024, stood at US$0.28 billion in 2025 and is projected to advance at a resilient CAGR of 6.0% from 2025 to 2030, culminating in a forecasted valuation of US$0.37 billion by the end of the period. Behind this steady surge lies a critical mission—ensuring biologics are safe, compliant, and globally trusted. With biosimilar and biologic approvals accelerating, and regulatory oversight tightening across FDA, EMA, and ICH, residual DNA testing has become non-negotiable for biopharma leaders.
The shift from small molecules to monoclonal antibodies, gene therapies, and vaccines has made biologics the backbone of modern medicine. With that evolution comes a heightened risk of contamination and compliance failure. Residual host cell DNA must be measured with high precision and consistency—this testing isn't just regulatory—it's a guarantee of clinical safety and product integrity.
Residual DNA testing eliminates a multi-million-dollar compliance and quality risk. Whether you're manufacturing biosimilars or cutting-edge cell therapies, undetected host cell DNA could derail product safety, delay regulatory approvals, or damage brand trust. This testing ensures batch reliability, boosts regulatory confidence, and enables fast-track market access.
Emerging markets like India , China , Brazil , and Japan are rapidly scaling their biopharma capabilities. A case in point: Sun Pharma's acquisition of Concert Pharmaceuticals in 2023 signalled deeper commitments to immunotherapy and innovation. These regions are investing in precision testing and validation tools, making them ripe for residual DNA tech adoption as they chase global compliance standards.
Together, the —but room remains for disruptors.
Despite the growth, standardization remains the Achilles' heel. Differing protocols for DNA extraction, assay validation, and quantification are stalling global harmonization. Companies must invest in platform standardization, cross-site validation, and training frameworks to ensure regulatory alignment and scalable operations. In a global market, consistency is currency.
In a biologics-led future, residual DNA testing is the new quality currency. It secures regulatory approvals, mitigates safety risks, and drives brand equity. Leaders who invest early in scalable, standardized DNA testing frameworks will define the next wave of biopharma growth.
For more information,
Get access to the latest updates on and
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, , and . With a , we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our , which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/residual-dna-testing-to-hit-370m-by-2030--the-silent-guardian-of-biologics-safety--marketsandmarkets-302495385.html